THG
DEAD

Serial Number

77388972

Owner

TheraGenetics Limited

Attorney

Lisa A. Osman

Filing Date

Feb 5, 2008

Add to watchlist:

No watchlists yet
View on USPTO

THG Trademark

Serial Number: 77388972

THG is a trademark filed by TheraGenetics Limited on February 5, 2008. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

TheraGenetics Limited (8 trademarks)

Inst.of Psychiatry, Kings College London
Denmark Hill, London SE58AF , GB

Entity Type: 03

Trademark Details

Filing Date

February 5, 2008

Registration Date

Not Registered

Goods & Services

Medical diagnostic services; diagnostic testing relating to the human body, namely, diagnostic testing and analysis of samples, in order to predict response of individuals to pharmaceutical products and treatments for disorders of the central nervous system, diagnostic testing and analysis of samples in order to predict response of individuals to pharmaceutical products and treatments for psychiatric disorders, diagnostic testing and analysis of samples in order to confirm diagnosis of diseases and disorders of the central nervous system, and diagnostic testing and analysis of samples in order to confirm diagnosis of Psychiatric diseases and disorders; clinical services, namely, the analysis of samples of DNA, RNA and bodily tissues in order to prescribe the pharmaceutical product or treatment best suited to the patient (i.e. the pharmaceutical product likely to have the most beneficial effect and/or the one with fewest or least severe side effects), the taking of samples of bodily tissues for analysis in connection with the prescription of pharmaceuticals, or other medical treatment, and medical and scientific research in the nature of conducting clinical trials; compilation of medical reports, relating to prediction of response of individuals to pharmaceutical products and treatments for disorders of the central nervous system; compilation of medical reports, relating to confirmation of diagnosis of diseases and disorders of the body, and prescription of most efficient and efficacious pharmaceutical product or method for treatment thereof; compilation of medical reports, namely, a resource of phenotypic and genotypic data relating to diseases and disorders of the central nervous system and psychiatric diseases and disorders; conducting of medical examinations for diagnosis of treatments; testing and profiling for medical purposes; computer aided diagnostic testing services relating to the human body

Advisory services relating to diagnostic preparations and products, namely, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for psychiatric disorders, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of diseases and disorders of the central nervous system, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of Psychiatric diseases and disorders, and consulting and advisory services relating to the provision of goods containing reagents for use in the collection and testing of DNA, RNA and bodily tissues; advisory services relating to diagnostic apparatus and diagnostic instruments, namely, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for psychiatric disorders, relating to apparatus and instruments used in the prediction of the response of individuals to pharmaceutical products and treatment for diseases and disorders of the central nervous system, relating to apparatus and instruments used in the prediction of the response of individuals to pharmaceutical products and treatment for psychiatric diseases and disorders, consulting and advisory services relating to the development, testing and efficacy, of apparatus and diagnostic instruments for the treatment of diseases and disorders of the central nervous system, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of psychiatric diseases and disorders, in connection with assays or assay kits for use in the collection and testing of DNA, RNA and bodily tissues, and in connection with assay kits (which may contain reagents) for use in the collection of DNA, RNA and bodily tissues; design and control of pharmacogenetic diagnostic tests for prediction of response of individuals to pharmaceutical products and treatments, for disorders of the central nervous system; design and control of pharmacogenetic diagnostic tests for prediction of response of individuals to pharmaceutical products and treatments, for psychiatric disorders; design and control of pharmacogenetic diagnostic tests for disorders and diseases of the central nervous system; design and control of pharmacogenetic diagnostic tests for psychiatric diseases and disorders; design and control of pharmacogenetic tests, including the devising, compiling and testing of algorithms and mathematical systems for predicting response to a pharmaceutical product based on individual genetic profile; scientific research related to pharmacogenetics; research and advisory services relating to pharmaceuticals

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jan 19, 2010 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 19, 2010 ABN2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jun 23, 2009 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jun 23, 2009 GNSI
SUSPENSION INQUIRY WRITTEN
Jun 23, 2009 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 23, 2009 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 23, 2008 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 23, 2008 GNSL
SUSPENSION LETTER WRITTEN
Dec 23, 2008 CNSL
EXAMINER'S AMENDMENT ENTERED
Dec 23, 2008 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 23, 2008 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 23, 2008 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 23, 2008 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 11, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 11, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 9, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 24, 2008 GNRN
NON-FINAL ACTION E-MAILED
Nov 24, 2008 GNRT
NON-FINAL ACTION WRITTEN
Nov 24, 2008 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 5, 2008 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 6, 2008 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 5, 2008 GNRN
NON-FINAL ACTION E-MAILED
May 5, 2008 GNRT
NON-FINAL ACTION WRITTEN
May 5, 2008 CNRT
ASSIGNED TO EXAMINER
Apr 29, 2008 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Mar 19, 2008 AMPX
ASSIGNED TO LIE
Mar 13, 2008 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Feb 15, 2008 PARI
NOTICE OF PSEUDO MARK MAILED
Feb 9, 2008 MPMK
NEW APPLICATION ENTERED
Feb 8, 2008 NWAP